Citalopram

Results: 177



#Item
121A:�alopram ped review.doc

A:alopram ped review.doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-11-13 08:05:26
122Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology

Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology

Add to Reading List

Source URL: www.fda.gov

Language: English
123Tablets/Oral Solution  Rev[removed]Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa.

Tablets/Oral Solution Rev[removed]Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa.

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-11-13 08:05:27
124Pediatric Focused Safety Review: escitalopram oxalate (Lexapro®) Pediatric Advisory Committee Meeting May 2011 Alyson Karesh, MD; Medical Officer

Pediatric Focused Safety Review: escitalopram oxalate (Lexapro®) Pediatric Advisory Committee Meeting May 2011 Alyson Karesh, MD; Medical Officer

Add to Reading List

Source URL: www.fda.gov

Language: English
125C:�a�Documents�RO��exaPeds�exareview.DOC

C:aDocumentsROexaPedsexareview.DOC

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-11-13 08:05:27
126By Elaine Gottlieb  Introduction Antidepressant medications are routinely prescribed for adolescents for a variety of psychiatric disorders, including depression, which affects five percent of children and adolescents at

By Elaine Gottlieb Introduction Antidepressant medications are routinely prescribed for adolescents for a variety of psychiatric disorders, including depression, which affects five percent of children and adolescents at

Add to Reading List

Source URL: www.mcpap.com

Language: English - Date: 2012-03-01 10:39:09
127dénomination  CITALOPRAM classe: N06A4 date de la baisse

dénomination CITALOPRAM classe: N06A4 date de la baisse

Add to Reading List

Source URL: www.sante.gouv.fr

- Date: 2013-11-15 10:04:38
    128Article	  DOI: [removed]bbeq[removed]INTELLECTUAL PROPERTY RIGHTS

    Article DOI: [removed]bbeq[removed]INTELLECTUAL PROPERTY RIGHTS

    Add to Reading List

    Source URL: s2b.mon.bg

    Language: English - Date: 2013-01-19 04:56:41
    129Jamie Wilkinson  MPharm(Hons), DipHE, MRPharmS Pharmaceuticals and Professional Affairs Adviser

    Jamie Wilkinson MPharm(Hons), DipHE, MRPharmS Pharmaceuticals and Professional Affairs Adviser

    Add to Reading List

    Source URL: www.ehealth2014.org

    Language: English - Date: 2014-06-25 05:15:06
    130BE – Lundbeck v. Tiefenbacher, Ratiopharm, Teva and Eurogenerics (escitalopram) Steven Cattoor HOYNG MONEGIER Less than a year after the first instance judgment of the Brussels Commercial Court (see http://www.eplawpat

    BE – Lundbeck v. Tiefenbacher, Ratiopharm, Teva and Eurogenerics (escitalopram) Steven Cattoor HOYNG MONEGIER Less than a year after the first instance judgment of the Brussels Commercial Court (see http://www.eplawpat

    Add to Reading List

    Source URL: www.eplawpatentblog.com

    Language: English - Date: 2012-09-24 12:01:00